作者
Géraldine Gebhart, LE Lamberts, Z Wimana, C Garcia, P Emonts, L Ameye, S Stroobants, M Huizing, P Aftimos, J Tol, WJG Oyen, DJ Vugts, OS Hoekstra, CP Schröder, T Guiot, AH Brouwers, A Awada, EGE de Vries, P Flamen
发表日期
2016/4/1
期刊
Annals of oncology
卷号
27
期号
4
页码范围
619-624
出版商
Elsevier
简介
Background
Only human epidermal growth factor receptor (HER)2 status determined by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) has been validated to predict efficacy of HER2-targeting antibody-drug-conjugate trastuzumab emtansine (T-DM1). We propose molecular imaging to explore intra-/interpatient heterogeneity in HER2 mapping of metastatic disease and to identify patients unlikely to benefit from T-DM1.
Patients and methods
HER2-positive mBC patients with IHC3+ or FISH ≥2.2 scheduled for T-DM1 underwent a pretreatment HER2-positron emission tomography (PET)/computed tomography (CT) with 89Zr-trastuzumab. [18F]2-fluoro-2-deoxy-D-glucose (FDG)–PET/CT was performed at baseline and before T-DM1 cycle 2. Patients were grouped into four HER2–PET/CT patterns according to the proportion of FDG-avid tumor load showing relevant 89Zr-trastuzumab uptake …
学术搜索中的文章
G Gebhart, LE Lamberts, Z Wimana, C Garcia… - Annals of oncology, 2016